Optimi Health (TSE:OPTI) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Optimi Health Corp. has partnered with ATMA Journey Centers to supply GMP psilocybin for Phase II clinical trials aimed at treating Major Depressive Disorder. The agreement, which covers territories including North America and the EU, positions Optimi as the sole supplier, with plans for a future collaboration on Phase III trials in 2025. This strategic alliance is anticipated to enhance accessibility and cost-effectiveness of psychedelic-assisted therapies, while ensuring high-quality standards and regulatory compliance.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.